Bronchiectasis
Massive hemoptysis (coughing up large amounts of blood), acute respiratory distress, cyanosis, high fever with general deterioration, or rapid worsening of dyspnea in a person with known bronchiectasis constitute medical emergencies. Severe hemoptysis, in particular, can be fatal and requires immediate hospitalization.
Call 911 immediately.
Pathophysiological mechanism
Bronchiectasis results from a well-documented vicious cycle, known as the Cole vicious cycle: an initial insult to the airways (infectious, inflammatory, or obstructive) impairs mucociliary clearance and promotes bacterial colonization. Colonizing bacteria trigger an excessive local inflammatory response, releasing proteases and inflammatory mediators that progressively destroy elastin, collagen, and muscle tissue in the bronchial walls. The resulting bronchial dilation is irreversible and, in turn, worsens mucus stasis, perpetuating the cycle.
Causes and associated conditions
Bronchiectasis is a common final manifestation of many distinct conditions. Identifying the underlying cause is essential for tailoring treatment and slowing disease progression.
| Category | Main causes |
|---|---|
| Infectious (post-infectious) | Severe or recurrent bacterial pneumonia, pulmonary tuberculosis (a major cause worldwide), whooping cough, serious viral infections of childhood (adenovirus, measles), nontuberculous mycobacteria (NTM) |
| Obstructives | Unretrieved inhaled foreign body, endobronchial tumor, extrinsic compressive adenopathy, chronic mucus plug |
| Genetic and congenital | Cystic fibrosis (mucoviscidosis): most frequent genetic cause; primary ciliary dyskinesia (Kartagener syndrome); alpha-1-antitrypsin deficiency; pulmonary sequestration |
| Immunological | Primary immunodeficiencies (common variable immunodeficiency, Bruton's agammaglobulinemia), IgG subclass deficiencies, HIV infection with advanced immunosuppression |
| Inflammatory and autoimmune | Rheumatoid arthritis, Sjögren's syndrome, inflammatory bowel disease (IBD), allergic bronchopulmonary aspergillosis (ABPA) |
| Inhalation and reflux | Chronic inhalation of irritant substances, repeated micro-aspirations linked to severe, uncontrolled gastroesophageal reflux |
| Idiopathic | No cause identified despite an exhaustive workup, representing 26 to 53 % of cases depending on the series |
Clinical manifestations
The clinical picture of bronchiectasis is dominated by chronic respiratory symptoms, with intercurrent acute exacerbations related to bacterial infections.
| Symptom or sign | Clinical characteristics |
|---|---|
| Chronic productive cough | Cardinal sign, present in over 90 % of patients; daily expectorations, often mucopurulent or purulent, more abundant in the morning upon waking and when in the lateral decubitus position |
| Purulent expectorations | Yellow or green secretions during stable periods, becoming more abundant and fetid during infectious exacerbations; daily volume varies from a few milliliters to several hundred milliliters in severe cases |
| Exertional dyspnea | Proportional to the degree of obstruction and the extent of the lesions; may progress to resting dyspnea in advanced stages |
| Hemoptysis | Present in 50 to 70 % of patients during the course of the disease; most often minor (bloody streaks in sputum); rarely massive and potentially fatal |
| Chest pain | Pleuritic chest pain during exacerbations, chronic chest heaviness or discomfort |
| General symptoms | Chronic fatigue, progressive weight loss in advanced forms, fever during bacterial exacerbations |
| Pulmonary auscultation | Crackles and sub-crepitant rales, rhonchi, sometimes wheezing in case of associated bronchospasm; clubbing (watch glass nails) in severe chronic forms |
Common colonizing bacterial agents
Chronic bronchial colonization by pathogenic bacteria is a central element of the pathophysiology and guides the choice of antibiotic therapies during exacerbations.
| Microorganism | Clinical significance |
|---|---|
| Haemophilus influenzae | Most common colonizing agent in non-cystic fibrosis bronchiectasis; associated with chronic bronchitis inflammation and frequent exacerbations |
| Pseudomonas aeruginosa | Poor prognostic colonizer; associated with accelerated progression, impaired quality of life, and higher mortality; frequent multidrug resistance |
| Staphylococcus aureus | Including MRSA strains; frequent in cystic fibrosis and in immunocompromised patients |
| Moraxella catarrhalis | Agent for moderate exacerbations, especially in elderly patients with concomitant COPD |
| Non-tuberculous mycobacteria (NTM) | Mycobacterium avium complex (MAC) notably; suspected in cases of middle lobe bronchiectasis in an elderly woman (Lady Windermere syndrome) |
| Aspergillus fumigatus | Can cause allergic bronchopulmonary aspergillosis (ABPA) or colonize bronchiectatic cavities; requires specific antifungal treatment |
Diagnosis
The diagnosis of bronchiectasis is made by high-resolution computed tomography (HRCT) of the chest, which is the gold standard examination. Standard chest X-rays are insufficient to establish the diagnosis with certainty.
- High-resolution computed tomography (HRCT) of the chest: reference examination; highlights the "airway thickening" sign (bronchial dilation with thickened walls), loss of the normal broncho-arterial ratio (greater than 1), mucus plugging, and extent of lesions
- Spirometry with flow-volume curve: evaluates the degree of bronchial obstruction (FEV1, FVC, Tiffeneau ratio) and functional severity
- Sputum culture with antibiogram: identification of colonizing agents and guidance of antibiotic therapy during exacerbations
- Etiological assessment: serum immunoglobulin levels (IgG, IgA, IgM, IgG subclasses), sweat test (cystic fibrosis if not done), autoimmune screening (RF, ANA), aspergillus serology and precipitins (ABPA), HIV screening depending on context
- Evaluation of primary ciliary dyskinesia: nasal nitric oxide measurement, ciliary motility analysis by electron microscopy, and molecular genetics if clinically suspected
- Bronchial endoscopy: indicated if suspicion of localized endobronchial obstruction, foreign body, or for deep microbiological sampling
- Arterial blood gas analysis and the six-minute walk test in moderate to severe forms to assess gas exchange and exercise tolerance
- Severity Score: Calculation of the Bronchiectasis Severity Index (BSI) for stratifying the risk of mortality and hospitalization
Therapeutic support
The treatment of bronchiectasis is chronic, multimodal, and individualized. No treatment can restore damaged bronchial architecture; the goal is to reduce the frequency of exacerbations, improve secretion clearance, preserve lung function, and optimize quality of life.
| Intervention | Modalities and Objectives |
|---|---|
| Respiratory physiotherapy and bronchial drainage | Pillar of daily treatment; autogenic drainage techniques, active cycle of breathing techniques (ACBT), oscillating devices (Acapella, Flutter, VestAirway); objective: mobilize and expectorate accumulated secretions, ideally once or twice a day |
| Antibiotic treatment of exacerbations | Guided by the sputum culture antibiogram; usual duration of 14 days; oral route if mild to moderate exacerbation, intravenous if severe or with Pseudomonas |
| Long-term suppressive antibiotic therapy | Indicated for three or more exacerbations per year; azithromycin three times a week (anti-inflammatory and antibacterial properties); inhaled antibiotics (tobramycin, aztreonam, colistin) in colonized patients Pseudomonas |
| Inhaled bronchodilators | Long-acting beta-2 agonists and long-acting anticholinergics if bronchial obstruction or bronchospasm is documented; they also facilitate secretion mobilization before physiotherapy. |
| Mucolysis and humidification of the airways | Hypertonic saline serum at 7% % for nebulization (improves mucociliary clearance); inhaled mannitol in certain cases; dornase alfa (Pulmozyme) is reserved for cystic fibrosis and contraindicated in non-CF bronchiectasis. |
| Vaccination | Annual influenza vaccination and routine pneumococcal vaccination to reduce the risk of viral and bacterial exacerbations |
| Respiratory rehabilitation | Structured program of exercise training, therapeutic education, and psychosocial support; improves exercise tolerance, reduces dyspnea, and improves quality of life |
| Surgical treatment | Pulmonary resection (lobectomy or segmentectomy) for refractory localized bronchiectasis with recurrent exacerbations despite optimal medical treatment; emergency bronchial artery embolization for severe hemoptysis; lung transplantation in end-stage cases |
Long-term follow-up and monitoring
- Annual spirometry to document the progression of lung function and detect progressive deterioration
- Periodic sputum cultures (at least once a year during stable periods and at each exacerbation) to monitor the microbiological profile and emerging resistance
- Regular clinical assessment of exacerbation frequency, exercise tolerance, and quality of life (bronchiectasis-specific QoL-B questionnaire)
- Thoracic CT scan for clinical worsening or suspicion of new complication (abscess, pneumothorax, lesion progression)
- Monitoring of oxygen saturation at rest and during exertion; ambulatory oxygen therapy if significant desaturation is documented.
- Screening and treatment of associated comorbidities: COPD, asthma, gastroesophageal reflux, malnutrition, depression
- Annual reassessment of suppressive treatment in patients on long-term antibiotic therapy (tolerance, resistance, side effects)
Consult at Clinique Omicron
In cases of chronic productive cough, recurrent lung infections, or progressively worsening shortness of breath, Clinique Omicron’s physicians and nurse practitioners (NPs) can initiate the appropriate clinical and functional assessment, prescribe necessary investigations including spirometry, and refer to pulmonology for diagnostic confirmation with high-resolution CT scans and the implementation of a personalized treatment plan. Coordinated follow-up for chronic respiratory diseases is provided at all Clinique Omicron service points in Quebec. Book an appointment online or by phone at one of our service points on the South Shore and elsewhere in Quebec.
The content of this page is provided for informational purposes only and is not intended to replace the advice of a qualified healthcare professional. Consult a physician for any symptoms, questions or decisions you may have regarding your health.
Omicron Clinic
Need to consult a doctor?
Treatment within 24-48 hours. In-clinic or telemedicine, anywhere in Quebec.
Insurance receipts. 7j/7. No family doctor required.